Tirzepatide and sulfur burps: GIP receptor-mediated gastric effects — 6 month update

LibrarianMeg said:

The line between titrate-through and stop is not severity, it is trajectory and what else is present.

No disagreement with LibrarianMeg. One condition attached. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

MikeKY_noInsulin said:

True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…

That reframing is the part I needed.

LibrarianMeg said:

The line between titrate-through and stop is not severity, it is trajectory and what else is present.

I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.

Adding the numbers, since they settle part of this. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.